Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The parameter that best correlates with 5 years disease-free survival (DFS ) in patients
(pts) with localized rectal cancer (RC) is the pathological TNM staging (ypTNM) after
chemo-radiotherapy (Ch-RT). DFS is 97% in pts with ypT0N0M0 = ypCR and 42% in pts with ypN +.
Standard 5-FU Ch-RT achieves 15% of ypCR. The use of IMRT achieves a high proportion of ypCR
. This study aimed to demonstrate in a prospective manner the feasibility of personalizing Ch
regimen base in TT in combination with IMRT in patients with RC. Secondary objectives
included the number of ypCR and safety.